Search Results

Esperion bagged broader-than-expected FDA labels for its cholesterol-busting drugs Friday, allowing the biotech to target seven times as many people in the U.S. compared to the old labels.

Esperion (NASDAQ: ESPR) today announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets based on positive CLEAR Outcomes data that include indications for cardiovascular risk reduction and expanded LDL-C lowering in both primary and secondary prevention patients.

Wednesday’s settlement resolves a legal dispute between Daiichi Sankyo Europe and Esperion Therapeutics regarding milestone payments under their cardiovascular drug collaboration.

For Daiichi Sankyo, recent results from the Phase III CLEAR trial of Esperion Therapeutics’ Nexletol (bempedoic acid) were not convincing enough to trigger a milestone payment.

With the results from the CLEAR outcomes study, Esperion is poised for a major inflection in sales and is targeting blockbuster status, said CEO Sheldon Koenig on an investor call Monday.

Esperion (NASDAQ: ESPR) today announced the publication of data from a pooled analysis of patients enrolled in four Phase 3 bempedoic acid studies in the Journal of Clinical Lipidology.

Products getting regulatory approval and hitting the market doesn’t always spell success for companies, especially during a global pandemic. Michigan-based Esperion has learned that lesson all too well.

Esperion (NASDAQ: ESPR), today announced that the company will participate in fireside chats at the following conferences:

Esperion announced the completion of an amendment to the EU commercial collaboration agreement with Daiichi Sankyo Europe.